424 related articles for article (PubMed ID: 15667868)
1. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
2. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
[TBL] [Abstract][Full Text] [Related]
3. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
4. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Desgrandchamps F; De La Taille A; Doublet JD;
BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763
[TBL] [Abstract][Full Text] [Related]
5. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
6. Prostate size influences the outcome after presenting with acute urinary retention.
McNeill AS; Rizvi S; Byrne DJ
BJU Int; 2004 Sep; 94(4):559-62. PubMed ID: 15329112
[TBL] [Abstract][Full Text] [Related]
7. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
8. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
9. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction.
Alan McNeill S
Eur Urol; 2004 Mar; 45(3):325-32. PubMed ID: 15036678
[TBL] [Abstract][Full Text] [Related]
10. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
McNeill SA; Hargreave TB;
J Urol; 2004 Jun; 171(6 Pt 1):2316-20. PubMed ID: 15126812
[TBL] [Abstract][Full Text] [Related]
11. Definition of at-risk patients: dynamic variables.
Emberton M
BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
[TBL] [Abstract][Full Text] [Related]
12. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Roehrborn CG
Prostate Cancer Prostatic Dis; 2006; 9(2):121-5. PubMed ID: 16304557
[TBL] [Abstract][Full Text] [Related]
13. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Resnick MI; Roehrborn CG
Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
[TBL] [Abstract][Full Text] [Related]
14. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
[TBL] [Abstract][Full Text] [Related]
15. The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
Annemans L; Cleemput I; Lamotte M; McNeill A; Hargreave T
BJU Int; 2005 Sep; 96(4):566-71. PubMed ID: 16104911
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
17. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.
Lucas MG; Stephenson TP; Nargund V
BJU Int; 2005 Feb; 95(3):354-7. PubMed ID: 15679793
[TBL] [Abstract][Full Text] [Related]
18. The natural history of benign prostatic hyperplasia.
Fitzpatrick JM
BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
[TBL] [Abstract][Full Text] [Related]
19. The Reten-World survey of the management of acute urinary retention: preliminary results.
Emberton M; Fitzpatrick JM
BJU Int; 2008 Mar; 101 Suppl 3():27-32. PubMed ID: 18307683
[TBL] [Abstract][Full Text] [Related]
20. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
